Antituberculosis drugs may induce hematologic side effects such as thrombocytopenia and neutropenia, but agranulocytosis has rarely been reported. We describe a patient who developed agranulocytosis induced by ethambutol.

A 79-year-old man was referred to our hospital for fever and skin rash showed no further improvement with antipyretic drug and fluid therapy on 3 weeks after taking antituberculosis drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) at other hospital. Three weeks ago, he was diagnosed with pulmonary tuberculosis by positive acid-fast bacilli. Complete blood count (CBC) at the time of diagnosis of pulmonary tuberculosis was white blood cell (WBC) of 6.70×10³/µL, absolute neutrophil count (ANC) of 3.37×10³/µL, hemoglobin of 11.9 g/dL, and platelet of 323×10³/µL. He denied other medical disease except the known pulmonary tuberculosis.

On the seventh admission day, agranulocytosis was developed with ANC of 70/µL. The patient had WBC of 1.63×10³/µL, hemoglobin of 12.2 g/dL, and platelet of 310×10³/µL. We stopped all antituberculosis drugs, and then treated with granulocyte colony-stimulating factor, subcutaneous dose of 300 µg of biosimilar filgrastim. Three days later, the number of WBC was 8.46×10³/µL and the number of ANC was 3.15×10³/µL (Figure 1). And then he was administered only isoniazid again for 3 days. Since there was no adverse effects, we added pyrazinamide and ethambutol, respectively with an interval. However, we stopped ethambutol due to fever and skin rash arised after adding ethambutol. There were no adverse effects of isoniazid and pyrazinamide for several days, so we added rifampicin and added ethambutol again with an interval. However, due to relapse of neutropenia (ANC of 1.43×10³/µL) in the sixth day after administrating ethambutol, we stopped ethambutol. And we continued isoniazid, rifampicin, and pyrazinamide for 9 months. He was cured without any other hematologic disorders.

Judging from the clinical course, we could conclude that ethambutol had caused agranulocytosis (Table 1).

Antituberculosis drugs have been shown to produce adverse effects from insignificance to life-threatening. In an immunocompetent patient, neutropenia is rare adverse effects of antituberculosis therapy. However, neutropenia combined with sepsis could lead to life-threatening. Umeki1 reported that the incidence rate of neutropenia and agranulocytosis due to antituberculosis drugs were observed in 10.9% and 3.96%, respectively. Shishido et al.2 reported that the incidence rate of agranulocytosis due to antituberculosis drugs was estimated at 0.06%. Therefore, it is important to detect neutropenia earlier and treat it in a patient taking antituberculosis drugs.

The causes of agranulocytosis mentioned above1,2 were not ethambutol, but rifampicin and isoniazid. The important adverse effects of ethambutol are visual disturbance due to retrobulbar neuritis and toxicities to peripheral nerves3,4. There is no well-documented report of agranulocytosis induced by ethambutol. Though Wong and Yew5 suggested an association of neutropenia (ANC of 1.4×10³/µL) with ethambutol, but it was not agranulocytosis, but mild neutropenia.

Our case is the first report of agranulocytosis induced by ethambutol. According to the previous reports1,2,6,7, neutropenia can be developed in a patient who is treated with antituberculosis drugs during a few months after starting administration. In administrating antituberculosis drugs including ethambutol, as in our case, we should regularly make a close monitoring of the CBC to avoid serious events.